We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

Today, the Natural History Museum, London, announced the first new permanent gallery to open since 2016, Fixing Our Broken Planet, which will open 3 April 2025. The gallery and a new programme of ...

Mike Ralston, CEO of Blencowe Resources (BRES) and Manuel Pablo Zúñiga-Pflücker, President and CEO of PetroTal (PTAL) will be presenting and taking live Q&A at focusIR's Investor Webinar on Tuesday ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

In early UK corporate news, housebuilder Barratt Redrow said it expects annual profit to land at the top end of consensus. Merchant bank Close Brothers revealed a GBP165 million provision set aside in ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...